CRISPR/Cas9-generated mouse model of Duchenne muscular dystrophy recapitulating a newly identified large 430 kb deletion in the human DMD gene

Autor: Svetlana G. Vassilieva, Dmitry V. Vlodavets, A. V. Polikarpova, Alexey A. Gavrilov, Denis A. Reshetov, Sergey V. Ulianov, Vladimir L. Buchman, Evgenia D. Zotova, Alexei V. Deykin, Tatiana V. Egorova
Jazyk: angličtina
Rok vydání: 2019
Předmět:
0301 basic medicine
Male
Duchenne muscular dystrophy
Medicine (miscellaneous)
lcsh:Medicine
medicine.disease_cause
New deletion
Dystrophin
Exon
0302 clinical medicine
Muscle degeneration
Immunology and Microbiology (miscellaneous)
CRISPR
Muscular dystrophy
Child
Base Pairing
Sequence Deletion
Mutation
Muscles
Exons
Chromatin
Biomechanical Phenomena
Phenotype
Female
Exon skipping
RNA
Guide
Kinetoplastida

Genome editing
lcsh:RB1-214
musculoskeletal diseases
congenital
hereditary
and neonatal diseases and abnormalities

Neuroscience (miscellaneous)
Computational biology
Biology
General Biochemistry
Genetics and Molecular Biology

Frameshift mutation
Cell Line
Mouse model
03 medical and health sciences
DMD
medicine
lcsh:Pathology
Animals
Humans
Resource Article
lcsh:R
medicine.disease
Mice
Inbred C57BL

Muscular Dystrophy
Duchenne

Disease Models
Animal

030104 developmental biology
biology.protein
CRISPR-Cas Systems
030217 neurology & neurosurgery
Zdroj: Disease Models & Mechanisms, Vol 12, Iss 4 (2019)
Disease Models & Mechanisms
ISSN: 1754-8411
1754-8403
Popis: Exon skipping is a promising strategy for Duchenne muscular dystrophy (DMD) disease-modifying therapy. To make this approach safe, ensuring that excluding one or more exons will restore the reading frame and that the resulting protein will retain critical functions of the full-length dystrophin protein is necessary. However, in vivo testing of the consequences of skipping exons that encode the N-terminal actin-binding domain (ABD) has been confounded by the absence of a relevant animal model. We created a mouse model of the disease recapitulating a novel human mutation, a large de novo deletion of exons 8-34 of the DMD gene, found in a Russian DMD patient. This mutation was achieved by deleting exons 8-34 of the X-linked mouse Dmd gene using CRISPR/Cas9 genome editing, which led to a reading frame shift and the absence of functional dystrophin production. Male mice carrying this deletion display several important signs of muscular dystrophy, including a gradual age-dependent decrease in muscle strength, increased creatine kinase, muscle fibrosis and central nucleation. The degrees of these changes are comparable to those observed in mdx mice, a standard laboratory model of DMD. This new model of DMD will be useful for validating therapies based on skipping exons that encode the N-terminal ABD and for improving our understanding of the role of the N-terminal domain and central rod domain in the biological function of dystrophin. Simultaneous skipping of exons 6 and 7 should restore the gene reading frame and lead to the production of a protein that might retain functionality despite the partial deletion of the ABD.
Summary: The authors describe the creation of a mouse strain that reproduces a newly identified deletion mutation in a DMD patient in Russia, and present the characteristics of this new model.
Databáze: OpenAIRE